《大行報告》高盛下調中生製藥(01177.HK)目標價至5.66元 評級「買入」
高盛發表報告指,受到新冠疫情影響,中生製藥(01177.HK)去年下半年銷售按年升8.6%至136億元人民幣,遜於該行預期。管理層維持今年收入按年升雙位數,以及在2020年至2030年期間複合年增長率介乎12%至15%等指引不變,同時又指,即使公司致力節約成本,但由於整合F-Star及研發投入,或會令今年盈利承壓。
該行降中生製藥今年至2025年各年純利預測分別14.2%、11.3%及10.7%,並將其目標價由5.88元下調至5.66元,維持其評級為「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.